Board of Directors

Chairman
Kapil Dhingra, MBBS
Chairman
Kapil Dhingra, MBBS
Kapil Dhingra, MBBS
Dr. Dhingra is a medical oncologist and a physician-scientist with a proven track record in academic research, patient care, and drug development. He served as Vice President, Head of the Oncology Disease Biology Leadership Team and Head of Oncology Clinical Development at Hoffmann-La Roche (“Roche”), during which he led numerous drug approvals, including Herceptin®, Tarceva®, and Avastin®. Prior to joining Roche, he worked in the oncology clinical development group at Eli Lilly and Company. Dr. Dhingra has served as a faculty member at The University of Texas M.D. Anderson Cancer Center, Indiana University School of Medicine, and Memorial Sloan Kettering Cancer Center. Dr. Dhingra is currently a member of the Boards of Directors of Black Diamond Therapeutics, Inc., Replimune, Inc., Five Prime Therapeutics, Inc., Autolus Therapeutics plc, and Median Technologies, and he has previously served on the boards of several successful biotech companies, including Biovex, Micromet, Algeta, YM Biosciences, Epitherapeutics, Advanced Accelerator Applications, and Exosome Diagnostics. He is a member of the NCI Experimental Therapeutics Panel. Dr. Dhingra founded KAPital Consulting, LLC in 2008, a company dedicated to helping biotechnology, pharmaceutical, and diagnostic companies realize the clinical and commercial advances in oncology. Dr. Dhingra obtained his M.B.B.S. degree from the All India Institute of Medical Sciences in New Delhi, India. He completed his residency in internal medicine at Lincoln Medical and Mental Health Center, New York Medical College and completed his fellowship in hematology and oncology at Emory University School of Medicine.
Director
Laia Crespo, PhD
Laia Crespo
Director
Laia Crespo, PhD
Laia Crespo
Laia Crespo, PhD
Laia joined Sanofi Ventures in 2018 with a background in biotech investing primarily in Europe. Prior to Sanofi, Laia served as Investment Director for Ysios Capital, a Venture fund based in Barcelona, where she led investments and served on the Boards of OxThera (Sweden), Minoryx Therapeutics (Spain) and Inbiomotion (Spain), and as an Observer with AM-Pharma (The Netherlands). Earlier in her career, Laia was part of the European New Business Development team of Janssen-Cilag, a pharmaceutical company of the Johnson & Johnson group, where she assessed commercial and scientific licensing-in opportunities. Previously she worked as a researcher in the UK in companies such as Spirogen (now AstraZeneca), Medivir and UCB-Celltech. Laia currently serves as a board observer for NodThera. Laia graduated in Chemistry from the University of Barcelona, where she also completed a Master in Science and a PhD with honors. Laia holds an MBA from Cambridge Judge Business School, University of Cambridge.
Director
Reza Halse, PhD
Reza Haize
Director
Reza Halse, PhD
Reza Haize
Reza Halse, PhD
Reza has over twelve years of therapeutic discovery and development experience in the pharmaceutical and biotechnology industries through management roles in the UK and US. In the UK he established research operations and led drug discovery efforts at Xcellsyz Ltd, a venture capital backed start-up, which was sold in 2004. He then moved to Novartis Pharmaceuticals in Cambridge, MA, where he directed drug discovery projects in a variety of disease areas, ranging from diabetes to neglected infectious diseases. While at Novartis he also established innovative drug discovery collaborations with academia and non-profit organizations, in an initiative aimed at incubating new areas of research. Following Novartis, he joined a well-capitalized biotech organization, funded by a venture philanthropist, and led programs at various stages of discovery and development using an entirely virtual operating model. Rez holds a BSc in Biochemistry and a PhD in cell biology both from Newcastle University, UK. Rez currently represents the Fund on the Boards of Adheron Therapeutics, Spero Therapeutics and Project C.
Director
Nanna Lüneborg, PhD
Nanna Luneborg
Director
Nanna Lüneborg, PhD
Nanna Luneborg
Nanna Lüneborg, PhD
Nanna joined Novo Holdings in 2012, and spent four years in Novo Seeds, where she helped build a strong portfolio of seed and Series A stage companies. She led the initial investments and served on the Boards as Director or Observer at Inthera, IO Biotech, MinervaX, Pcovery, Forendo and Galecto. Nanna joined Novo Ventures in 2016 and has been involved in both private and public investments, including successful public listings of Orphazyme (ORPHA), ObsEva (OBSV), and Inventiva (IVA). She currently serves on the boards of NodThera, ReViral, Stargazer and Lava. Prior to her time at Novo Holdings, Nanna was part of the life science investment team at Apposite Capital, a London-based venture fund, where she participated in both primary and secondary investments, with multiple deals leading to highly successful exits for the fund, including Convergence, Ulthera and Cancer Partners UK. She has previously worked at Cancer Research UK as a research analyst, and as a consultant to various biotech and healthcare venture projects during her MBA. Nanna received her PhD in Neuroscience from University College London, an MBA with distinction from University of Cambridge, and a 1st class BA from University of Oxford.
Director
Stefan Luzi, PhD
Stefan Luzi
Director
Stefan Luzi, PhD
Stefan Luzi
Stefan Luzi, PhD
Stefan Luzi joined Gilde Healthcare in 2015. He is focusing on venture and growth capital investments in the biopharmaceutical and life science instruments sectors. He led the investment in Lava Therapeutics B.V. and was part of several other investments. He represents Gilde on the boards of Lava Therapeutics B.V. and Lumicks B.V. Prior to joining Gilde, Stefan worked at Merck KGaA where he completed several international assignments including the Global Business Intelligence and MS Ventures divisions. Additionally, he was involved in various consulting projects spanning the pharmaceutical and chemical departments at Merck and co-moderated Merck Serono’s innovation competitions. Stefan holds a MSc in Biotechnology degree from ETH Zurich (Switzerland) and a MPhil in Bioscience Enterprise degree from the University of Cambridge (UK). He also completed a PhD program with Sir Gregory Winter at the MRC Laboratory of Molecular Biology in Cambridge (UK), where he developed a bicyclic peptide-based drug discovery platform.
Director
Guido Magni, MD, PhD
Guido_Magni
Director
Guido Magni, MD, PhD
Guido_Magni
Guido Magni, MD, PhD
Guido Magni, M.D., Ph.D., is a Partner with Versant Ventures. He brings deep experience in drug development from multiple accomplishments at leading global pharmaceutical companies including Roche and Wyeth. Guido held the position of Global Head of the Medical Science Department at Roche for 12 years and built a track record that includes the approval of 15 new drugs across various therapeutic areas during this time, including blockbuster products Cellcept, Pegasys, Mabthera, Xeloda, Herceptin, Tamiflu and Tarceva. Guido brings this critical expertise to Versant portfolio companies by providing guidance on their clinical and regulatory strategies.
Director
Joël Jean-Mairet, PhD
Joel Jean Mariet
Director
Joël Jean-Mairet, PhD
Joel Jean Mariet
Joël Jean-Mairet, PhD
Joël is managing partner and co-founder of Ysios Capital. Previously, he co-founded Glycart Biotechnology in 2001 and was its CEO until it was successfully sold to F. Hoffmann La-Roche four years later. Glycart Biotechnology was the originator of the anti-CD20 antibody – obinituzumab/Gazyva®, the first breakthrough designated drug approved by the FDA for B-CLL. He holds an MS in Biotechnology and a PhD from the Swiss Federal Institute of Technology (ETH) in Zurich. Joël is currently on the boards of directors of Aura Biosciences, Sanifit Therapeutics, Ona Therapeutics, Executive Chairman of Inbiomotion, Chairman of SpliceBio and board observer at AM-Pharma. He has been Chairman of the board of Cellerix/Tigenix (now Takeda), board observer at Biovex (now Amgen). Joël has earned numerous awards, including the Wall Street Journal’s Europe Innovation Award in 2001.  
Erik van den Berg
Erik van dan Berg
Erik van den Berg
Erik van dan Berg
Erik van den Berg
Erik has over twenty years of experience in the pharmaceutical industry. He is the CEO of AM-Pharma and board member of several (bio)tech companies. Previously, as a senior executive at Organon (currently Merck) he was responsible for leading the Company’s global biotechnology business development. Erik executed over 20 transactions and partnerships, most recently a $600M option to acquire AM-Pharma by Pfizer and raised more than €130M in equity and debt financing. He concluded his Masters in chemistry from the University of Utrecht and an MBA from Manchester Business School both with honors.